NuOnc’s At-Home Program Translates a Controversial Cancer Theory Into Daily Glucose Readings

For a patient navigating the exhausting cycles of cancer treatment, the space between appointments can feel like a void. It is there, in the long stretches of waiting and recovery, that NuOnc is placing its bet. The digital health startup, operating under the brand MyMetabolism, offers an eight-week, coached program designed to help patients manage their metabolic health at home, using daily glucose and ketone tracking as its north star [PERPLEXITY SONAR PRO BRIEF]. The approach is not a treatment, but a form of structured support, translating decades of specialized academic research into a daily routine of finger pricks and dietary adjustments.

Its scientific foundation comes from Dr. Thomas Seyfried, a Boston College professor and cancer metabolism researcher whose work forms the core of the protocol [PERPLEXITY SONAR PRO BRIEF]. The company’s premise is that by helping patients reach and maintain a specific Glucose Ketone Index (GKI), it can provide a non-pharmaceutical complement to standard oncology care, leaving all medication decisions firmly with the clinical team [PERPLEXITY SONAR PRO BRIEF]. This is a delicate space to operate in, one where patient hope meets clinical caution, and where digital health tools must walk a fine line between empowerment and overreach.

The Seyfried Protocol, Packaged for Home Use

At its heart, MyMetabolism is an attempt to productize a specific school of thought. Dr. Seyfried’s ‘Press-Pulse’ protocol pairs a therapeutic ketogenic diet, which restricts glucose and glutamine, with pulsed adjuncts like certain drugs or hyperbaric oxygen. His model posits that cancer cells are fundamentally crippled by a lack of these fermentable fuels and cannot effectively utilize ketone bodies for energy. NuOnc’s program focuses on the dietary and monitoring component, acting as a ‘health copilot’ that provides personalized nutrition, lifestyle guidance, and GKI tracking with a connected meter [PERPLEXITY SONAR PRO BRIEF].

The program is built around getting patients into a therapeutic GKI range, a metric the company says is backed by approximately 30 years of research [PERPLEXITY SONAR PRO BRIEF]. It includes blood-panel-informed adjustments and human coaching support, aiming to translate complex metabolic concepts into actionable daily steps. For the company, the product wedge is this translation layer,taking research often confined to academic papers and early-phase trials and making it accessible for daily life [PERPLEXITY SONAR PRO BRIEF].

A Student-Led Venture with Expert Advisers

The team behind NuOnc is young, but it has enlisted notable advisers to anchor its scientific credibility. Co-founders Lucas Lu, a Boston College student, and Federico Fernandez-Kepka, a graduate student at Harvard Medical School, launched the company in 2024 [PERPLEXITY SONAR PRO BRIEF][12]. Lu’s background is in finance, with prior experience at TD Securities and Sustainable Impact Capital, while Fernandez-Kepka lists strategic planning and business development for MyMetabolism among his roles [PERPLEXITY SONAR PRO BRIEF][10].

Their most critical asset is Dr. Seyfried himself, who serves as a scientific adviser [PERPLEXITY SONAR PRO BRIEF]. The company also lists Lavinia Errico, co-founder of Equinox and an investor in wellness, as an adviser [PERPLEXITY SONAR PRO BRIEF][8]. This structure,student operators guided by established experts,is a common archetype in university-born biotech, though it places a heavy burden on the advisers’ ongoing involvement and the founders’ ability to navigate the regulated health landscape.

Role	Name	Key Background
Co-Founder	Lucas Lu	Boston College student; finance background (TD Securities, Sustainable Impact Capital) [PERPLEXITY SONAR PRO BRIEF][8]
Co-Founder	Federico Fernandez-Kepka	Harvard Medical School graduate student; focus on digital health and cancer metabolism
Scientific Adviser	Dr. Thomas Seyfried	Professor of Biology at Boston College; leading researcher in cancer metabolism [PERPLEXITY SONAR PRO BRIEF][19]
Adviser	Lavinia Errico	Co-founder of Equinox; founder of Joylift and MOVEJOY; investor at First Point Partners [PERPLEXITY SONAR PRO BRIEF][8]

Early Signals and the Path to Validation

As a pre-seed company, NuOnc’s traction is measured in early interest rather than clinical outcomes. Co-founder Lucas Lu’s LinkedIn profile has reported a waitlist of 4,600 emails and a company valuation of $500,000, though these are self-reported figures without independent verification [LinkedIn]. The MyMetabolism service itself shows signs of user engagement, with one review platform listing an overall rating of 3.72/5 from 18 reviews, and the service claiming over 2,400 verified customer reviews for a weight management program [19][15]. A patient testimonial cited in marketing materials describes the GKI tracking and AI coach as “life-changers” during recovery from Stage 2 cancer.

These are the early validation signals common to direct-to-consumer digital health: waitlists, reviews, and anecdotal reports. The far harder, and necessary, validation will be clinical. The program is based on research from phase 1 and 2 trials, but the MyMetabolism offering itself is not a regulated therapeutic device and does not require FDA clearance. Its success will depend on demonstrating consistent user adherence, gathering real-world data, and, ultimately, partnering with clinical researchers to study its impact on patient-reported outcomes within the context of comprehensive cancer care.

Navigating a Field of Caution and Hope

The metabolic theory of cancer is a compelling but contentious area of oncology. While it has a dedicated following and ongoing research, it is not the dominant paradigm in standard oncologic care, which remains centered on surgery, radiation, chemotherapy, immunotherapy, and targeted therapies. This context defines both NuOnc’s opportunity and its most significant risk. The company is entering a sensitive market where patients are often seeking any edge they can find, and where the line between supportive care and alternative treatment can blur dangerously.

The risks for NuOnc are substantial and multifaceted.

• Clinical integration. The program exists outside the traditional care pathway. Without formal partnerships with oncology practices or integration into electronic health records, it risks being perceived as an isolated wellness tool rather than a complementary medical support.
• Evidence threshold. While based on published research, the specific MyMetabolism protocol’s effect on quality of life or treatment tolerance lacks peer-reviewed study. In the eyes of many clinicians, anecdotal success stories are not a substitute for controlled trial data.
• Regulatory posture. The company carefully states it leaves medication decisions to medical teams, positioning itself as a lifestyle program [PERPLEXITY SONAR PRO BRIEF]. Maintaining this distinction is crucial to avoid regulatory scrutiny that applies to products making disease treatment claims.

For patients with solid tumors exploring metabolic interventions, the current standard of care offers little structured support. Dietary advice from oncology teams is often generic, and the burden of tracking biomarkers like glucose falls entirely on the patient and their family. It is a gap filled by books, online forums, and a patchwork of nutritionists, not by integrated digital tools. NuOnc is attempting to build that tool, offering a measured, coached protocol where there is often only overwhelming information and uncertainty.

The next twelve months will be about moving from waitlist to a sustainable service. The company must convert early interest into retained subscribers, begin to systematically collect outcomes data, and navigate the crucial conversations with clinical institutions. Its bet is that a humane, technology-enabled approach to a complex metabolic protocol can carve out a meaningful niche in cancer supportive care. For the patients it aims to serve, that niche represents something simple yet profound: a sense of agency and a daily metric of progress, in a journey where both are often in short supply.

Sources

1. [PERPLEXITY SONAR PRO BRIEF] NuOnc, research brief
2. [LinkedIn] Lucas Lu - Co-Founder @ NuOnc (MyMetabolism) | https://www.linkedin.com/in/lucas0408/
3. [Boston College Magazine, Fall 2025] SSC Venture Partners | https://www.bc.edu/bc-web/sites/bc-magazine/fall-2025-issue/features/ssc-venture-partners.html
4. [MyMetabolism] About MyMetabolism, Why we built it | https://mymetabolism.life/about
5. [MyMetabolism] MyMetabolism, The program that gets you into therapeutic GKI. | https://www.mymetabolism.com/
6. [MyMetabolism] MyMetabolism
7. [Wikipedia, Retrieved 2026] Thomas N. Seyfried - Wikipedia | https://en.wikipedia.org/wiki/Thomas_N._Seyfried
8. [Boston College, Retrieved 2026] Thomas N. Seyfried - Biology Department - Boston College | https://www.bc.edu/bc-web/schools/morrissey/departments/biology/people/faculty-directory/thomas-seyfried.html
9. [adammendler.com, Retrieved 2026] Interview Transcript: Equinox Co-Founder Lavinia Errico | https://www.adammendler.com/blog/lavinia-errico/
10. [LinkedIn, 2026] Mark Li - MS in Health Informatics @ Yale | https://www.linkedin.com/in/mark-tlx-li/
11. [LinkedIn, 2026] Weiyi (Sunny) Fu - Taobao Marketplace | https://www.linkedin.com/in/weiyi-sunny-fu/
12. [LinkedIn, 2026] Hannah 吳恩怡 Ng - Century 21 Cedarcrest Realty, Inc. | https://www.linkedin.com/in/hannah-ng13/
13. [ResearchGate, Retrieved 2026] Thomas Seyfried's research works | Boston College, Boston (BC) and other places | https://www.researchgate.net/scientific-contributions/Thomas-Seyfried-2076504366
14. [EverybodyWiki Bios & Wiki, Retrieved 2026] Thomas N. Seyfried - EverybodyWiki Bios & Wiki | https://en.everybodywiki.com/Thomas_N._Seyfried
15. [MyMetabolism] 2,400+ verified customer reviews claim
16. [MyMetabolism] Patient testimonial reference
17. [abm Inc., Retrieved 2026] Dr. Thomas N. Seyfried: Redefining Cancer Treatment through Metabolic Research | https://info.abmgood.com/innohub-dr-seyfried
18. [Wikipedia, Retrieved 2026] Thomas N. Seyfried - Wikipedia (editorial boards)
19. [MyMetabolism] MyMetabolism overall rating claim
20. [MyMetabolism] Press-Pulse protocol description
21. [MyMetabolism] Description of Seyfried's metabolic model
22. [MyMetabolism] Seyfried quote on blocking fermentation fuels
23. [LinkedIn, 2026] Reference to Lavinia Errico as angel investor